Literature DB >> 24074765

The prognostic significance of sentinel node tumour burden in melanoma patients: an international, multicenter study of 1539 sentinel node-positive melanoma patients.

Augustinus P T van der Ploeg1, Alexander C J van Akkooi1, Lauren E Haydu2, Richard A Scolyer2, Rajmohan Murali3, Cornelis Verhoef1, John F Thompson2, Alexander M M Eggermont4.   

Abstract

INTRODUCTION: Sentinel node (SN) biopsy (SNB) and completion lymph node dissection (CLND) when SN-positive have become standard of care in most cancer centres for melanoma. Various SN tumour burden parameters are assessed to determine the heterogeneity of SN-positivity. The aim of the present study was to validate the prognostic significance of various SN tumour burden micromorphometric features and classification schemes in a large cohort of SN-positive melanoma patients.
METHODS: In 1539 SN-positive patients treated between 1993 and 2008 at 11 melanoma treatment centres in Europe and Australia, indices of SN tumour burden (intranodal location, tumour penetrative depth (TPD) and maximum size of SN tumour deposits) were evaluated.
RESULTS: Non-subcapsular location, increasing TPD and increasing maximum size were all predictive factors for non-SN (NSN) status and were independently associated with poorer melanoma-specific survival (MSS). Patients with subcapsular micrometastases <0.1mm in maximum dimension had the lowest frequency of NSN metastasis (5.5%). Despite differences in SN biopsy protocols and clinicopathologic features of the patient cohorts (between centres), most SN parameters remained predictive in individual centre populations. Maximum SN tumour size>1mm was the most reliable and consistent parameter independently associated with higher non-SN-positivity, poorer disease-free survival (DFS) and poorer MSS.
CONCLUSIONS: In this large retrospective, multicenter cohort study, several parameters of SN tumour burden including intranodal location, TPD and maximum size provided prognostic information, but their prognostic significance varied considerably between the different centres. This could be due to sample size limitations or to differences in SN detection, removal and examination techniques.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Melanoma; Pathology and survival; Sentinel node biopsy

Mesh:

Year:  2013        PMID: 24074765     DOI: 10.1016/j.ejca.2013.08.023

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  18 in total

Review 1.  Sentinel Lymph Node Biopsy and Completion Lymph Node Dissection for Melanoma.

Authors:  Sabran J Masoud; Jennifer A Perone; Norma E Farrow; Paul J Mosca; Douglas S Tyler; Georgia M Beasley
Journal:  Curr Treat Options Oncol       Date:  2018-09-19

Review 2.  Predicting the outcome of melanoma: can we tell the future of a patient's melanoma?

Authors:  Oriol Yélamos; Pedram Gerami
Journal:  Melanoma Manag       Date:  2015-08-10

3.  Is the non-sentinel lymph node compartment the next site for melanoma progression from the sentinel lymph node compartment in the regional nodal basin?

Authors:  Andrei Rios-Cantu; Ying Lu; Victor Melendez-Elizondo; Michael Chen; Alejandra Gutierrez-Range; Niloofar Fadaki; Suresh Thummala; Carla West-Coffee; James Cleaver; Mohammed Kashani-Sabet; Stanley P L Leong
Journal:  Clin Exp Metastasis       Date:  2017-07-11       Impact factor: 5.150

Review 4.  Clinical utilities and biological characteristics of melanoma sentinel lymph nodes.

Authors:  Dale Han; Daniel C Thomas; Jonathan S Zager; Barbara Pockaj; Richard L White; Stanley Pl Leong
Journal:  World J Clin Oncol       Date:  2016-04-10

5.  Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy.

Authors:  Alexander M M Eggermont; Vanna Chiarion-Sileni; Jean-Jacques Grob; Reinhard Dummer; Jedd D Wolchok; Henrik Schmidt; Omid Hamid; Caroline Robert; Paolo A Ascierto; Jon M Richards; Céleste Lebbé; Virginia Ferraresi; Michael Smylie; Jeffrey S Weber; Michele Maio; Lars Bastholt; Laurent Mortier; Luc Thomas; Saad Tahir; Axel Hauschild; Jessica C Hassel; F Stephen Hodi; Corina Taitt; Veerle de Pril; Gaetan de Schaetzen; Stefan Suciu; Alessandro Testori
Journal:  N Engl J Med       Date:  2016-10-07       Impact factor: 91.245

6.  Therapeutic Value of Sentinel Lymph Node Biopsy in Patients With Melanoma: A Randomized Clinical Trial.

Authors:  Jessica S Crystal; John F Thompson; John Hyngstrom; Corrado Caracò; Jonathan S Zager; Tiina Jahkola; Tawnya L Bowles; Elisabetta Pennacchioli; Peter D Beitsch; Harald J Hoekstra; Marc Moncrieff; Christian Ingvar; Alexander van Akkooi; Michael S Sabel; Edward A Levine; Doreen Agnese; Michael Henderson; Reinhard Dummer; Rogerio I Neves; Carlo Riccardo Rossi; John M Kane; Steven Trocha; Frances Wright; David R Byrd; Maurice Matter; Eddy C Hsueh; Alastair MacKenzie-Ross; Mark Kelley; Patrick Terheyden; Tara L Huston; Jeffrey D Wayne; Heather Neuman; B Mark Smithers; Charlotte E Ariyan; Darius Desai; Jeffrey E Gershenwald; Shlomo Schneebaum; Anja Gesierich; Lisa K Jacobs; James M Lewis; Kelly M McMasters; Cristina O'Donoghue; Andre van der Westhuizen; Armando Sardi; Richard Barth; Robert Barone; J Greg McKinnon; Craig L Slingluff; Jeffrey M Farma; Erwin Schultz; Randall P Scheri; Sergi Vidal-Sicart; Manuel Molina; Alessandro A E Testori; Leland J Foshag; Lisa Van Kreuningen; He-Jing Wang; Myung-Shin Sim; Richard A Scolyer; David E Elashoff; Alistair J Cochran; Mark B Faries
Journal:  JAMA Surg       Date:  2022-09-01       Impact factor: 16.681

7.  Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual.

Authors:  Jeffrey E Gershenwald; Richard A Scolyer; Kenneth R Hess; Vernon K Sondak; Georgina V Long; Merrick I Ross; Alexander J Lazar; Mark B Faries; John M Kirkwood; Grant A McArthur; Lauren E Haydu; Alexander M M Eggermont; Keith T Flaherty; Charles M Balch; John F Thompson
Journal:  CA Cancer J Clin       Date:  2017-10-13       Impact factor: 508.702

Review 8.  Current management of melanoma patients with nodal metastases.

Authors:  Dale Han; Alexander C J van Akkooi; Richard J Straker; Adrienne B Shannon; Giorgos C Karakousis; Lin Wang; Kevin B Kim; Douglas Reintgen
Journal:  Clin Exp Metastasis       Date:  2021-05-07       Impact factor: 4.510

9.  Survival of sentinel node biopsy versus observation in intermediate-thickness melanoma: A Dutch population-based study.

Authors:  R M H Roumen; M S Schuurman; M J Aarts; A J G Maaskant-Braat; G Vreugdenhil; W J Louwman
Journal:  PLoS One       Date:  2021-05-25       Impact factor: 3.240

10.  Pembrolizumab in the adjuvant treatment of melanoma: efficacy and safety.

Authors:  Caroline A Nebhan; Douglas B Johnson
Journal:  Expert Rev Anticancer Ther       Date:  2021-02-14       Impact factor: 3.627

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.